Coultreon Biopharma Appoints Nate Massari as Chief Business OfficerNate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first-in-class SIK3 inhibitor COL-5671
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical OfficerDr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671
